US FDA Cancer Drug Dosage Optimization Guidance Will Increase Exposure To Ineffective Agents, NCI Says

 
• By Sue Sutter
Population growth
National Cancer Institute says new FDA draft guidance will subject a substantial number of additional patients to dose optimization studies of ineffective or non-viable agents. • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards